Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
We generated a comprehensive atlas of the immunologic cellular networks within human malignant pleural mesothelioma (MPM) using mass cytometry. Data-driven analyses of these high-resolution single-cell data identified 2 distinct immunologic subtypes of MPM with vastly different cellular composition, activation states, and immunologic function; mass spectrometry demonstrated differential abundance of MHC-I and -II neopeptides directly identified between these subtypes. The clinical relevance of this immunologic subtyping was investigated with a discriminatory molecular signature derived through comparison of the proteomes and transcriptomes of these 2 immunologic MPM subtypes. This molecular signature, representative of a favorable intratumoral cell network, was independently associated with improved survival in MPM and predicted response to immune checkpoint inhibitors in patients with MPM and melanoma. These data additionally suggest a potentially novel mechanism of response to checkpoint blockade: requirement for high measured abundance of neopeptides in the presence of high expression of MHC proteins specific for these neopeptides.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 3×
“However, in many instances, tumor mutation burden and prediction of neoantigen burden do not correlate with response to checkpoint blockade (21, 25, 45, 46, 57).”
BackgroundResultGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 1×
“in metastatic melanoma patients treated with anti–PD-1 antibodies (n = 27) (43).”
BackgroundClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
COSMIC: somatic cancer genetics at high-resolution
Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C. G., Ward, S., Dawson, E., Ponting, L., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1121 · Cited by 1,922
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
Cited by
Clinical Significance of Histologic Subtyping of Malignant Pleural Mesothelioma
Brcic, L., & Kern, I. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.38 · Cited by 77
“In many clinical trials where there was obvious clinical benefit of immunotherapy, it was regardless of PDL1 expression (63-66).”
BackgroundMesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
Cersosimo, F., Barbarino, M., Lonardi, S., Vermi, W., Giordano, A., Bellan, C., & Giurisato, E. (2021) · Cancers · doi:10.3390/cancers13225664 · Cited by 41
Napoli, F., Listì, A., Zambelli, V., Witel, G., Bironzo, P., Papotti, M., Volante, M., Scagliotti, G., & Righi, L. (2021) · Cancers · doi:10.3390/cancers13112564 · Cited by 22
“On the other hand, a comprehensive proteomic analysis on 12 surgically resected MPMs highlighted a correlation between the presence of activated pDCs (CD40+ and CD86+) and tumors having a good TIME signature as well as a favorable response to immune checkpoint therapy [33].”
Background
Metadata
- Authors
- Lee, H.-S., Jang, H.-J., Choi, J. M., Zhang, J., de Rosen, V. L., Wheeler, T. M., Lee, J.-S., Tu, T., Jindra, P. T., Kerman, R. H., Jung, S. Y., Kheradmand, F., Sugarbaker, D. J., & Burt, B. M.
- Venue
- JCI Insight
- Published
- 2018-04-05
- Volume
- 3
- Issue
- 7
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W2795557894
- Cited by
- 55
- References
- 16
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. https://app.cochat.ai/papers/10.1172/jci.insight.98575
- The paper
- Lee, H.-S., Jang, H.-J., Choi, J. M., Zhang, J., de Rosen, V. L., Wheeler, T. M., Lee, J.-S., Tu, T., Jindra, P. T., Kerman, R. H., Jung, S. Y., Kheradmand, F., Sugarbaker, D. J., & Burt, B. M. (2018). Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight. https://doi.org/10.1172/jci.insight.98575
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.